Medtronic Held 44% of the Bone Graft Substitute Market in 2010

Laura Dyrda -   Print  |
Medtronic leads the bone graft substitute market with 44 percent market share of the $1.9 billion market, according to a report from Global Pipeline Analysis. Medtronic's success in the market has been driven by its bone morphogenic protein product, Infuse, which has recently been the focus of controversial new studies suggesting it is associated with a higher number of complications that industry-funded studies suggested.

In the future, the market is expected to be driven by orthopedic procedures and an increase in the aging population who will benefit from them. The report predicts there will also be an increase in preference for bone graft substitutes during replacement and autograft procedures. As the market becomes more lucrative, more companies such as Synthes, Wright Medical, Orthovita, Stryker and Osteotech have increased their presence.

In 2010, Medtronic had more than 90 percent share in the global BMP market, valued at $868 million.

Read the release about the bone graft substitute market.

Related Articles on the Orthopedics Market:

Orthopedic and Spine Device Industry Post-Reform: 6 Challenges

Healthcare Reform Act's Impact on Orthopedic and Spine Device Companies: Q&A With Kristian Werling of McGuireWoods

The Big Companies Keep Growing Bigger: 15 Recent Orthopedic Device Company Partnerships and Acquisitions



© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers